▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1782 by analyst upside · 2026-06-27
XENE
Xenon Pharmaceuticals Inc.
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+34.9%
implied upside to consensus target
Current Price $59.74
Consensus Target $80.56
Bull Target $100.0
Bear Target $63.0
Analysts Covering 19
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
16
Hold
0
Sell
0
52-Week Low $30.0
52-Week High $63.95
YTD Return +34.3%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E -11.9x
EPS (TTM) $-4.70
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $30.0
52-Week High $63.95
Current Price $59.74
Bear Target $63.0
Bull Target $100.0
● Now $59.74 ● Target $80.56
TRADING DATA
Avg Volume 1.1M
YTD Return +34.3%
Analyst Count 19
Consensus Buy
Upside to Target +34.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Xenon Pharmaceuticals Inc. (XENE) is currently trading at $59.74 with a Wall Street consensus price target of $80.56, implying potential upside of 34.9% over the next 12 months. 19 analysts currently cover XENE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $100.0, while the most cautious has a target of $63.0.

XENE operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 34.3% year-to-date and is currently trading near the upper end of its 52-week range of $30.0 – $63.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +47.0%
Grifols, S.A.
$5B · P/E 10.6x · Buy
INDV +21.2%
Indivior Pharmaceuticals, Inc.
$5B · P/E 21.2x · Buy
STVN +37.1%
Stevanato Group S.p.A.
$5B · P/E 30.8x · Buy
PACS +18.6%
PACS Group, Inc.
$7B · P/E 27.0x · Buy
ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for XENE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan — Reiterated
Overweight → Overweight 2026-05-27 43% win rate (7 calls)
JP Morgan — Reiterated
Overweight → Overweight 2026-05-12 43% win rate (7 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-05-08 Building track record
Needham — Reiterated
Buy → Buy 2026-05-08 20% win rate (5 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-03-16 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-03-10 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-03-10 Building track record
Deutsche Bank — Reiterated
Buy → Buy 2026-03-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
68
out of 100
Coverage depth
23/30
Consensus clarity
18/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →